Trials / Completed
CompletedNCT04838743
GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.
A Non-interventional, Single-arm, Multicentre, Prospective Study Investigating the Glycaemic Control and Treatment Pattern Associated With the Use of Xultophy® (IDegLira) in a Real-world Adult Population With Type 2 Diabetes Mellitus in Japan. GOAL (Glycaemic Outcome Assessment IDegLira) Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 244 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect information on how Xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes. Participants will get Xultophy® as prescribed by the study doctor. The study will last for about 26 weeks. Participants will be asked questions about health and diabetes treatment and lab tests as part of normal doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDegLira | Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan. The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study. |
Timeline
- Start date
- 2021-04-23
- Primary completion
- 2022-10-26
- Completion
- 2022-10-26
- First posted
- 2021-04-09
- Last updated
- 2025-12-31
Locations
42 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04838743. Inclusion in this directory is not an endorsement.